Interview with Loucif Ouyahia, Global Head of Digital Healthcare, Jazz Pharmaceuticals
When communicating to healthcare professionals, Pharma companies have new expectations, concerning what can be achieved. “We have ‘ChatGPT syndrome’, meaning that people expect results immediately from AI and a revolution in terms of the outputs,” says Loucif Ouyahia, Global Head of Digital Healthcare at Jazz Pharmaceuticals.
He will participate in a session entitled: “Measuring AI’s Impact: How GenAI Is Transforming Scientific Data Dissemination” at the NEXT Pharma Summit 2025 will run from May 20-21 in Dubrovnik, Croatia.
SciencePOD had the opportunity to speak with Loucif in advance of the event.
Could you describe your current role and main focus?
I have a PharmD qualification and Master’s degrees in Disruptive Innovation and Digital Healthcare Strategy. As head of Digital Healthcare at Jazz Pharma, I lead strategy building and its deployment. I work closely with Global Medical and Scientific Affairs, which encompasses approximately 80% of my duties. I also work closely with the Data & Analytics, Real-World Evidence and Patient Engagement teams.
Right now, I am focused on AI implementation, and the goal is to help people within the departments I collaborate with to improve their efficiency, free their time for more added value tasks, and improve our external scientific engagement impact.
What has been your experience in using AI for scientific data dissemination?
I think AI is extremely impactful. Before we even get to data dissemination, AI can play a huge role in data and insight collection and AI inputs during intermediary triage steps can also be very valuable. When we hire experts, we need them to focus on using their expertise, not added-value activities, such as data triage, so AI can play a very important role here.
In terms of data dissemination, we have explored AI for material creation, document summarisation, scientific materials analysis and insights extraction.
What is your view on using AI versus professional medical writers for dissemination?
In my vision, AI is not here to replace people. The reality is that people are being asked to do more and more with flat resources, and I see AI as being here to help them deal with the workload, be more efficient and focus on key expertise tasks. AI can handle more routine activities that do not require as much skill or expertise while letting people focus solely on their area of expertise.
This logic applies to medical writers, who can use AI as a tool in their arsenal. For instance, such writers can use AI for the first steps in summarising and building documents.
AI can still make mistakes, and so there is a need for an experienced human writer to review and improve its output. At present, no regulatory body can accept completely AI-generated results, and there must always be a human check.
“We have ‘ChatGPT syndrome’, meaning that people expect results immediately from AI and a revolution in terms of the outputs.”
Could you share some experience or anecdotes that have evolved your thinking around the use of AI in scientific dissemination and the lessons learned for the future?
I think we need to educate people about AI a little more. People have certain expectations of AI, and these are not grounded in reality. We have ‘ChatGPT syndrome’, meaning that folks expect results immediately from AI and a revolution in terms of the results.
So, it’s important that we educate people so that they have realistic expectations. People think that they can use AI like they use ChatGPT, ask a question and get a response within a few seconds. This may be possible for superficial and general questions, but for complex and extensive tasks, more time and technical experience is key.